144 related articles for article (PubMed ID: 38906371)
1. The lipopolysaccharide-TLR4 axis regulates hepatic glutaminase 1 expression promoting liver ammonia build-up as steatotic liver disease progresses to steatohepatitis.
Mercado-Gómez M; Goikoetxea-Usandizaga N; Kerbert AJC; Gracianteparaluceta LU; Serrano-Maciá M; Lachiondo-Ortega S; Rodriguez-Agudo R; Gil-Pitarch C; Simón J; González-Recio I; Fondevila MF; Santamarina-Ojeda P; Fraga MF; Nogueiras R; Heras JL; Jalan R; Martínez-Chantar ML; Delgado TC
Metabolism; 2024 Jun; 158():155952. PubMed ID: 38906371
[TBL] [Abstract][Full Text] [Related]
2. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
Zou Z; Liu X; Yu J; Ban T; Zhang Z; Wang P; Huang R; Zheng F; Chang Y; Peng W; Tang Y; Feng X; Zhao Z; Lv X; Huang S; Guo J; Tuo Y; Zhou Z; Liang S
J Hepatol; 2024 Jun; 80(6):834-845. PubMed ID: 38331323
[TBL] [Abstract][Full Text] [Related]
3. Hepatic NLRP3-Derived Hsp70 Binding to TLR4 Mediates MASLD to MASH Progression upon Inhibition of PP2A by Harmful Algal Bloom Toxin Microcystin, a Second Hit.
Roy S; Saha P; Bose D; Trivedi A; More M; Xiao S; Diehl AM; Chatterjee S
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003543
[TBL] [Abstract][Full Text] [Related]
4. Suppression of hepatic ChREBP⍺-CYP2C50 axis-driven fatty acid oxidation sensitizes mice to diet-induced MASLD/MASH.
Zhang D; Zhao Y; Zhang G; Lank D; Cooke S; Wang S; Nuotio-Antar A; Tong X; Yin L
Mol Metab; 2024 Jul; 85():101957. PubMed ID: 38740087
[TBL] [Abstract][Full Text] [Related]
5. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
[TBL] [Abstract][Full Text] [Related]
6. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
Burmeister Y; Weyer K; Dörre A; Seilheimer B
Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
[TBL] [Abstract][Full Text] [Related]
7. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
[TBL] [Abstract][Full Text] [Related]
8. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.
Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H
J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146
[TBL] [Abstract][Full Text] [Related]
9. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
Takahashi Y; Dungubat E; Kusano H; Fukusato T
Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
[TBL] [Abstract][Full Text] [Related]
10. RASSF4 Attenuates Metabolic Dysfunction-Associated Steatotic Liver Disease Progression via Hippo Signaling and Suppresses Hepatocarcinogenesis.
Xu C; Fang T; Qu J; Miao Y; Tian L; Zhang M; Zhuang H; Sun B; Chen L
Cell Mol Gastroenterol Hepatol; 2024 Apr; 18(2):101348. PubMed ID: 38697356
[TBL] [Abstract][Full Text] [Related]
11. Understanding gut-liver axis nitrogen metabolism in Fatty Liver Disease.
Delgado TC; de Las Heras J; Martínez-Chantar ML
Front Endocrinol (Lausanne); 2022; 13():1058101. PubMed ID: 36589817
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathogenesis of metabolic dysfunction-associated steatotic liver disease, steatohepatitis, hepatic fibrosis and liver cirrhosis.
Saito T; Tsuchishima M; Tsutsumi M; George J
J Cell Mol Med; 2024 Jun; 28(12):e18491. PubMed ID: 38894579
[TBL] [Abstract][Full Text] [Related]
13. Lipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD).
Syed-Abdul MM
Metabolites; 2023 Dec; 14(1):. PubMed ID: 38248815
[TBL] [Abstract][Full Text] [Related]
14. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.
; ; ;
Diabetologia; 2024 Jun; ():. PubMed ID: 38869512
[TBL] [Abstract][Full Text] [Related]
15. Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation.
Kjærgaard K; Daugaard Mikkelsen AC; Landau AM; Eriksen PL; Hamilton-Dutoit S; Magnusson NE; Thomsen MB; Chen F; Vilstrup H; Mookerjee RP; Bay-Richter C; Thomsen KL
JHEP Rep; 2024 Mar; 6(3):100992. PubMed ID: 38415019
[TBL] [Abstract][Full Text] [Related]
16. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Backer S; Khanna D
Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470
[TBL] [Abstract][Full Text] [Related]
17. Role of ammonia and glutamine in the pathogenesis and progression of metabolic dysfunction-associated steatotic liver disease: A systematic review.
Njei B; Al-Ajlouni YA; Ameyaw P; Njei LP; Boateng S
J Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38763916
[TBL] [Abstract][Full Text] [Related]
18. Time-of-day-dependent variation of the human liver transcriptome and metabolome is disrupted in MASLD.
Johanns M; Haas JT; Raverdy V; Vandel J; Chevalier-Dubois J; Guille L; Derudas B; Legendre B; Caiazzo R; Verkindt H; Gnemmi V; Leteurtre E; Derhourhi M; Bonnefond A; Froguel P; Eeckhoute J; Lassailly G; Mathurin P; Pattou F; Staels B; Lefebvre P
JHEP Rep; 2024 Jan; 6(1):100948. PubMed ID: 38125300
[TBL] [Abstract][Full Text] [Related]
19. EMC10 modulates hepatic ER stress and steatosis in an isoform-specific manner.
Chen K; Wang Y; Yang J; Klöting N; Liu C; Dai J; Jin S; Chen L; Liu S; Liu Y; Yu Y; Liu X; Miao Q; Liew CW; Wang Y; Dietrich A; Blüher M; Wang X
J Hepatol; 2024 Apr; ():. PubMed ID: 38599383
[TBL] [Abstract][Full Text] [Related]
20. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.
Foglia B; Sutti S; Cannito S; Rosso C; Maggiora M; Casalino A; Bocca C; Novo E; Protopapa F; Ramavath NN; Provera A; Gambella A; Bugianesi E; Tacke F; Albano E; Parola M
Front Immunol; 2024; 15():1342404. PubMed ID: 38469298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]